Introduction
Human immunodeficiency virus (HIV) encephalopathy covers a range of HIV-related central nervous system (CNS) dysfunction. The most severe is HIV-associated dementia (HAD). 1 The prevalence of HAD was estimated to be as high as 30% in patients with advanced AIDS, 2 but HAD has become less common since the introduction of highly active antiretroviral therapy (HAART). 3, 4 This reduction probably reflects better control of HIV in the periphery, since antiretroviral drugs penetrate the CNS poorly. A less fulminant form of HIV-related neurological dysfunction, minor cognitive/motor disorder (MCMD), has become more prevalent and remains a significant independent risk factor for AIDS mortality. 5, 6 Soluble gp120 can induce apoptosis in a wide variety of cells including lymphocytes, 7 cardiomyocytes 8 and neurons. [9] [10] [11] In the brain, HIV mainly replicates in microglial cells and minimally, if at all, in neurons. [12] [13] [14] At high concentrations, HIV gp120 may be directly neurotoxic. 15 That gp120 induces apoptosis has been shown by studies in cortical cell cultures, in rat hippocampal slices and by intracerebral injections in vivo. 16 HIV gp120 binds neuron cell membrane coreceptors (CCR3, CCR5 and CXCR4) and elicits apoptosis, apparently via G-protein coupled pathways. [17] [18] [19] [20] Soluble gp120 also increases glial cell release of arachidonate, which impairs neuron and astrocyte reuptake of glutamate 21 causing prolonged activation of N-methyl-Daspartate (NMDA) receptor which disrupts cellular Ca 2+ homeostasis and leads to neuron cell death. [22] [23] [24] In addition, NMDA receptor activation induces formation of inducible nitric oxide synthase (iNOS). Proinflammatory cytokines, TNF-a and TGF-b, also upregulate iNOS. 25, 26 Superoxide anion (O À 2 ), a byproduct of electron transport is produced by myeloid and monocytic cells upon HIV-1 infection. 27 Superoxide dismutase (SOD) scavenges O À 2 and converts it to peroxide (H 2 O 2 ). 28 Peroxide is then further detoxified by catalase or glutathione peroxidase. The later oxidizes glutathione.
HIV-infected individuals have impaired antioxidant defenses. 29 Poor SOD activity leads to elevated levels of reactive oxygen species (ROS), 30 which in turn leads to depletion of intracellular antioxidants such as glutathione (GSH). 31 Cellular vulnerability to oxidantrelated injury is made worse by the fact that nitric oxide (NO) generated by NMDA-R-activated iNOS readily binds superoxide anion to form the highly reactive species, peroxynitrite (ONOO) (O 2 À +NO-ONOO). 21, [32] [33] [34] Peroxynitrite reacts with and damages lipids, proteins and DNA. 35, 36 Here, we describe protection of CNS neurons from HIV-1 gp120 oxidant-related toxicity by gene delivery of antioxidant enzymes SOD1 and GPx1 using recombinant SV-40-derived vectors. These vectors readily transduce neurons in vitro and in vivo, and have been effective in studying gene transfer as protection from HIV-1 in experimental systems. [37] [38] [39] [40] [41] [42] We found that rSV40 gene delivery of transgenes SOD1 and GPx1, singly or in combination, significantly mitigated neuronal apoptosis mediated by gp120. The effectiveness and degree of protection of these vectors in delivering these antioxidant enzymes was also verified in vivo. Antioxidant gene delivery may thus be a future therapeutic adjunct in treating CNS AIDS.
Results

Characterization of neurons
Neurons were prepared from NT2 cells (NT2-N) as described in Materials and methods, by differentiation using retinoic acid and mitotic inhibitors. NT2-N could be seen with refractile small cell bodies and were interconnected with neuritic processes. The cells grew on a feeder layer of large adherent flat cells, which represent immature neurons ( Figure 1a) . The differentiated mature neurons were further characterized by immunohistochemical and Western analyses using antibodies vs the neuron-specific markers, MAP-2 and Neu-N (Figure 1b) . These NT2-N were positive for MAP-2 and NeuN, whereas undifferentiated NT2 cells were not. Western analysis demonstrated predominant protein bands at 280 and 70 kDa (high and low molecular weight isoforms) for MAP-2, and at 50 kDa for Neu-N (Figure 1c) . Again, undifferentiated NT-2 cells were negative for both.
Dose response of gp120 in neurons
The optimal concentration of HIV-1 Ba-L gp120 to elicit apoptosis in neurons was determined using NT2-N. Cells were incubated with 0, 0.1, 1, 10 and 100 ng/ml of recombinant soluble gp120 (Figure 2a and b) . Apoptotic bodies were analyzed using terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL). The intensity and frequency of TUNEL+ cells increased with increasing gp120 dose, up to 100 ng/ml. Higher concentrations of gp120 caused cells to detach and so were not further studied (data not shown). Thus 100 ng/ml of gp120 was used in all subsequent studies. 0 -deoxyuridine, uridine, (1-b-D-ribofuranosyluracyl) and cytosine-b-D-arabinofuranoside were added for 3 weeks. The differentiated neurons were further characterized using imunofluorescence (b) where NT2 progenitors and NT2-neurons were stained with antibodies vs the neuron-specific markers, MAP-2 and Neu-N. Immunostaining with an isotype-matched immunoglobulin is shown as a negative control. Western analysis (c) was also performed for MAP-2 and Neu-N using GAPDH was used as an internal loading control.
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Effectiveness of recombinant SV(SOD1) and SV(GPx1) in transducing NT2-N cells
Terminally differentiated NT2-N were transduced with MOI 10 of SV(SOD1) and SV(GPx1) on day 0, then again at MOI of 3 on days 3 and 5, for a cumulative MOI of 16. Alternatively, cells were transduced on the same schedule but with MOI ¼ 100, then 30 and again 30. For simplicity 10-3-3 regimen is referred to as MOI ¼ 10 and the latter regimen is referred to as MOI ¼ 100. The transduced neurons were analyzed for transgene expression after 2 weeks. Western analysis showed a predominant band at 22 kDa for SOD1 ( Figure 3a ) and 24 kDa for GPx1 (Figure 3b ) respectively, both of which were more abundant in transduced, as opposed to control, groups. Transduction at 100 MOI did not increase expression beyond what was observed with 10 MOI. The activity of enzymes delivered by these vectors was studied using kinetic assays for SOD1 and GPx1. There is a low background level of enzyme activity, since SOD1 and GPx1 are normal cellular enzymes. However, transduced cultures showed markedly and significantly increased activities of their respective enzymes, compared to control cultures (Figure 3c and d) . Again, increasing transduction MOI from 10 to 100 did not further increase enzyme activity. Therefore, in all subsequent experiments, transduction was carried out at MOI ¼ 10.
Protection of NT2-N from gp120 apoptosis by transduction with SV(SOD1) and SV(GPx1)
Having established that 100 ng/ml gp120 produced maximal apoptosis in cultured neurons, we tested whether delivery of antioxidant enzymes SOD1 or GPx1, singly or in combination, would protect NT2-N from gp120-induced programmed cell death. Control NT2-N were also transduced with SV(HBS) and were challenged with gp120 (100 ng/ml (0.9 nM)). Apoptosis was scored by counting total number of TUNEL positive cells in six different 10 Â fields. In control cultures, mock or SV(HBS)-transduced cells, resulted in 90-100% apoptosis. NT2-N transduced with SV(SOD1) and/or SV(GPx1) expressed substantially more of the antioxidant enzymes than did control cells, as analyzed by immunostaining and Western blotting ( Figure 4 ) and were 80% protected from apoptosis (Po0.005) as compared to mock-transduced neurons (Figure 4) . The background level of apoptosis in these cells was o2-5% and was comparable among all experimental and control groups (data not shown). The fluorescence intensity in the TUNEL assay was measured using IPLab software. Following gp120 exposure: for SV(HBS) transduced NT2-N, it was 98977124 (arbitrary units); for SV(SOD1)-treated NT2-N, it was 1565757; for SV(GPx1)-treated NT2-N, it was 1032743. Differences between antioxidant-treated and control cultures were highly significant (Po0.005). 3) were used to transduce the neurons, less protection was observed (data not shown). Combination transduction with both viruses (SOD1 and GPx1), provided B90% protection from gp120-induced apoptosis, which was slightly, but not significantly, better than either alone.
SV(SOD1) and SV(GPx1) protect primary fetal neurons from gp120 apoptosis
Having established that gp120-induced apoptosis could be prevented by transduction with SV(SOD1) and SV(GPx1) in cultured neurons derived from NT-2 cells, we tested whether primary human neurons responded similarly. That is, would transduction of primary neurons with SV(SOD1) or SV(GPx1) protect them from apoptosis induced by gp120? The cell populations used for the present studies were prepared from human fetal brain as described in Materials and methods and were 498% neurons, as indicated by positive staining for MAP-2 ( Figure 5a ). Transduction efficiency was comparable to NT2-N when assayed by immunostaining: 490% of these neurons were efficiently transduced with the vectors, either alone or in combination (data not shown). Test and control-transduced cells were then treated with recombinant gp120 and apoptosis was measured by TUNEL assay. Transduction with SV(SOD1) and/or SV(GPx1) largely (480%) and significantly (Po0.005) protected primary neurons from gp120-induced apoptosis ( Figure 5b ) as compared to neurons transduced with the control vector, SV(HBS). Combination transduction with SV(SOD1) plus SV(GPx1) provided protection from gp120-induced apoptosis comparable to that afforded by either antioxidant transgene singly. As with NT2-N, levels of apoptosis in transduced and control cultures that were not challenged with gp120 were comparable (data not shown).
Transgene expression and protection from gp120-induced apoptosis after injection of SV(SOD1)/ SV(GPx1) in vivo
We then asked whether SV(SOD1) and SV(GPx1) were capable of delivering their antioxidant enzymes to brain cells in vivo. SV(SOD1) and SV(GPx1) were injected stereotaxically into the rat caudate putamen (CP). The distribution of transgene expression was studied by immunocytochemistry ( Figure 6 ) and Western analysis (Figure 7a and b). Numerous transgene-positive cells were observed 1 week after injection of SV(SOD1) ( Figure 6 ). The number of cells expressing the transgenes detectably was somewhat higher when tested 14 days after vector injection as compared to 7-days ( Figure 6 ). When analyzed by Western blotting, high levels of transgene expression was detected both 7 and 14 days post-injection. Levels detected at the later time point were somewhat higher than at 7 days, possibly because the increased time elapsed allowed for greater protein accumulation (Figure 7a and b). Very few or no cells on the uninjected side were immunopositive for the transgenes. Also rats that were mock-transduced, or transduced with SV(BugT), showed minimal immunopositivity for SOD1. Most cells that were transduced in vivo were neurons, as shown by immunostaining with Neuro Trace (Nissl) which was used as marker for neurons ( Figure 6 ). Similar results were observed after injection into the CP with SV(GPx1) constructs in rat brain (data not shown). Western and kinetic analysis of SOD1 and GPx1. Western analysis of transduced differentiated neurons is shown in (a and b) for SV(SOD1) and SV(GPx1) respectively. Transduction using both SV(SOD1) and SV(GPx1) virus constructs yielded a predominant band at 22 kDa for SOD1 and 24 kDa band for GPx1. GAPDH was used as an internal loading control. For kinetic analysis NT-2N were transduced with SV(SOD1) and SV(GPx1) viruses on days 0, 3 and 5 with MOI 10, 3, 3, respectively, or MOI of 100, 30, 30. They were analyzed for activities of SOD1 (c) and GPx1 (d) 10 days later, using kinetic assays. Kinetic analysis was carried out using SOD1 and GPx1 kits according to manufacturer instructutions on Genesys 2 spectrophotometer (see Materials and methods).
Antioxidant enzyme gene delivery L Agrawal et al and/or SV(GPx1) to protect NT2-N from gp120 apoptosis is illustrated in the TUNEL (a), and was generated from three independent experiments in (b). At the time of assay, cells were tested for expression of transgenes by Western analysis (see insets). Inset panels show expression of SOD1 and GPx1 transgenes with single (above) and double (below) transduction. GAPDH was used as internal loading control. The cells were maintained for 5 days in DMEM supplemented with 2% fetal bovine serum before addition of recombinant gp120 (100 ng/ml (0.9 nM)) to the cultures for 2 days. The cells were washed and cultured for another 3 days before TUNEL assay.
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To test the effectiveness of SOD1 in protecting from HIV-1 gp120-induced apoptosis, we injected 100 ng of gp120 into the CP 2 weeks following injection of SV(SOD1). Intracerebral injection SV(SOD1) provided significant protection (480%) from gp120-induced apoptosis when measured by TUNEL as compared to control vector SV(BugT) (Figure 7c and d) . The majority of cells that were protected were found to be neurons (Figure 7c ).
Discussion
Neuron apoptosis is one of the mechanisms by which HIV causes CNS injury in AIDS patients. 43, 44 Many reports suggest that HIV-induced neuron injury involves free radicals, beginning with a series of reactions initiated at the cell membrane by gp120 to generate ROS culminating in neuronal apoptosis. There is no accepted therapy for HIV-induced neuron apoptosis and our approach, involving gene delivery, is unique to the best of our knowledge. Accordingly, we hypothesized that gene transfer for ROS detoxifying enzymes and other free radical scavengers may protect CNS cells from gp120-induced apoptosis. We thus asked whether HIV gp120 elicited apoptosis in neurons and, if so, whether the antioxidant enzymes SOD1 and GPx1 delivered by recombinant SV40 vectors could protect neurons.
We used two types of cells for these studies: NTera-2 cells, a human teratocarcinoma cell line that could be induced to differentiate into NT2-Neurons, 45, 46 and primary neurons derived from human fetal brain. 47 In both, mature neurons comprised 498% of the cultured cells as assessed by MAP-2 and Neu-N staining. These cells predominantly express HIV-coreceptors CCR5 with lesser amounts of CXCR4 and CCR3. 48 When exposed to HIV-BaL-gp120, both primary neurons and NT2-derived neurons underwent apoptosis in a dose-dependent manner, with maximal effect at 100 ng/ml gp120 (0.9 nM). This concentration of gp120 is consistent with doses of gp120 used in studies repeated by others examining HIV-1 induced neuronal apoptosis.
11,15,17 rSV40 gene delivery increased intracellular SOD1 and GPx1 and largely protected neurons from the effects of gp120. Cotransduction with SV(SOD1) and SV(GPx1) improved protection, slightly, but not statistically significant compared to either transgene alone.
These data are in agreement with previous reports that superoxide generated as a result of HIV infection of macrophages may be scavenged by SOD1 in a dosedependent manner and detoxified by very high concentrations of recombinant SOD1. 49 It is also possible that transduction with SOD1 might also mitigate the effects of HIV on microglial cells, which are the primary CNS targets for HIV infection and produce increased superoxide when exposed to HIV. The role of antioxidants has been studied in a variety of neurological disorders using several viral gene transfer vectors. Adenovirus containing Cu/Zn SOD-1 in cerebral vessels has shown to prevent cerebral blood flow autoregulation 50 and cerebral vasopasm 51 during acute stage of subarchnoid hemorrhage. Lentiviral vectors have also been used in targeting several genes involved in neurological disorders for efficient therapeutic intervention. 52 Overexpression of GPX in rat embryonic cortical neurons using adenoviral vector (Ad-GPX) increases resistance of neuronal cells to amyloid b-peptide (Ab) mediated neurotoxicity and has potential implications for gene therapy of Alzheimer's disease. 53 Overexpression of GPX using lentivirus vectors in nigral dopaminergic neurons in vivo has also been shown to be neuroprotective in murine models of Parkinsons disease. 54 Herpes Simplex viral vectors expressing GPX inhibit release of cytochrome c and proapoptotic mediators and protect neurons exposed to experimental stroke and necrotic insults. [55] [56] [57] Generation of ROS in response to HIV infection leads to shifts in intracellular redox balance. This causes depletion of antioxidant species such as glutathione, 31 and increases propensity to undergo apoptosis. 58 ONOO can cause cell death by several mechanisms, including nitration of tyrosine residues. Nitration of neurofilaments, actin and other structural proteins may disrupt filament assembly and impair cytoskeletal stability. 32 Our preliminary studies also indicate that gp120 may lead to increased protein nitration in neurons as well (Agrawal and Strayer, unpublished).
To determine whether the effectiveness of rSV40 vectors in antioxidant gene delivery to neurons in vitro might also be applicable in vivo, we also tested SV(SOD1) and SV(GPx1) delivery of antioxidant genes directly into the brain. Efficient transgene expression in the rat brain was noted after single injection into the CP: numerous cells, mostly neurons, expressed the transgene. We have previously reported that these vectors are effective transducing agents by intracerebral injection. 59 Numbers of transgene-expressing cells may be further increased using multiple inoculations. 60, 61 We also investigated neuronal apoptosis caused in vivo by recombinant gp120, preparatory to attempting to assess protection using these antioxidant transgene SV(SOD1).
In vivo transduction with SV(SOD1) substantially protected neurons from gp120-induced apoptosis, compared to in vivo injection of the control vector SV(BugT). Figure 6 Expression of SOD1 following injection of SV(SOD1) into the caudate-putamen (CP). SV(SOD1) was injected into the CP, while the contralateral CP was untreated. At 7 days (left panels) or 14 days (right panels) after administering SV(SOD1) into the CP, sections were immunostained for SOD1 (shown in red) and for Nissl a neuron marker (shown in green). Basal endogenous levels of SOD1 are shown in lane marked control rat. The uninjected side of SOD1-transduced rats and an unrelated SV(BugT) vector were used as negative controls. Cells that are positive for both neurotrace and SOD1 are in the overlay micrographs. Nuclei were also stained by DAPI.
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This is the first study to demonstrate that neurons can be protected from gp120-induced apoptosis by antioxidant gene transfer using SV40 vectors. We used rSV40s here since they are excellent delivery vehicles for neurons, both in vivo and in vitro. 59, [62] [63] [64] As a result of their transduction efficiency and effectiveness in mitigating gp120-induced apoptosis, these vectors may serve as investigative tools to elucidate mechanisms of neuron damage in HIV infection of CNS. Thus, detoxification of ROS by SV(GPx1) or SV(SOD1) protects from HIVinduced apoptosis and may serve as a potential gene therapy strategy for people with HIV encephalopathy.
Materials and methods
Plasmids and viral expression constructs SOD1 and GPx1 transgenes were subcloned in to pT7 [RSVLTR] . Transgene expression is controlled by the Rous Sarcoma Virus long terminal repeat (RSV-LTR) as a promoter. SV-HBS was used as negative control recombinant virus for in vitro experiments, which encodes Hepatitis B surface antigen.
42 SV(HBS) cannot be used for in vivo experiments because immunity to the expressed hepatitis surface antigen transgene leads to elimination of transduced cells in immunocompetent rats. SV(BugT) was used as negative control vector for in vivo studies. SV(BugT) carries the cDNA for human bilurubin-uridine 5 0 -diphosphate-glucuronysyl transferase (BugT), driven by two tandem SV40 early promoters (SV40-EP). 65 Generation of recombinant SV40 viruses has been reported in detail. 41 Briefly, recombinant viral genomes were transfected into COS-7 cells. We use COS-7 cells as a packaging cell line because they supply all SV-40 genes needed for virus packaging. Recombinant viral stocks were prepared as cell lysates and were purified using sucrose cushion. Virus stocks were titered by Q-PCR. 66 Cell lines. COS-7 cell line was obtained from American Type Culture Collection (ATCC) and was maintained in Dulbecco's modified eagle's medium (DMEM) supple- mented with 10% calf serum (Hyclone, Logan, UT, USA), 2 mM L-glutamine and containing 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 1.0 mM sodium pyruvate, penicillin (200 U/ml) and streptomycin (100 mg/ml). Human N-tera2/cloneD1 (NT-2), derived from a teratocarcinoma was obtained from Stratagene (La Jolla, CA, USA) and induced to differentiate into NT2-Neurons (NT2-N) according to manufacturer's instructions. The cells were propogated in DMEM with nutrient mixture F-12 (DMEM/F-12) supplemented with glutamine and 10% (v/v) calf serum. Differentiation to neurons was induced by adding 10 mM retinoic acid (Sigma Chemicals, MO, USA). After the first replating, the cells were treated with mitotic inhibitors: cytosine b-D-arabinofuranoside (ara C) (1 mM), uridine (1-b-D-ribofuranosyluracyl) (Urd) (10 mM) and 5-fluoro-2 0 -deoxyuridine) (FUDR) (10 mM) for 3 weeks. After further enrichment and selective trypsinization, highly enriched neurons were harvested 2-3 weeks later. The neurons culture obtained were 495% pure neurons and were plated on poly-D-lysine (Sigma Chemicals) and matrigel coated (BD Biosciences, Bedford, MA, USA) 4-chamber slides or 24-well tissue culture plates. The neurons were characterized using MAP-2 and Neu-N antibodies by immunostaining (Chemicon International Inc., Temecula, CA, USA). 45 Primary human fetal neuronal cells. Neurons were isolated from the fetal brain as described previously. were purchased from Charles River Laboratories (Wilmington, MA, USA). Protocols for injecting, and killing animals were approved by the Thomas Jefferson University Institutional Animal Care and Use Committee, and were consistent with AAALAC standards.
Transduction and challenge studies in vitro. COS-7 cells, NT-2 precursors or NT2-neurons were transduced with SV40-derived viruses SV(SOD1) and SV(GPx1) either singly or in combination on days 0, 3 and 5 with MOI of 10, 3 and 3, respectively. The cells were tested for transgene expression by Western analysis and immunostaining. The cells were maintained for 5 days in DMEM supplemented with 2% fetal bovine serum. The transduced and mock-trasnduced cells showed the same degree of viability (495%). Recombinant HIV-1-Ba-Lgp120 (AIDS Reagent Program, NIH) (100 ng/ml) (0.9 nM) was then added to the cultures for 2 days. The cells were washed and cultured for another 3 days before performing TUNEL assay (Roche, Indianapolis, IN, USA). The mean sum fluorescence intensity of TUNEL positive cells was calculated using IP Lab software and analyzed on fluorescence imaging/microscope (Olympus IX70).
In vivo transduction studies. The rats were anesthetized with isofluorane UPS gas (BaxterHealthcare Corp., Deerfield, IL, USA) (1.0 unit isofluorane/1.5 lO 2 per min) and placed in a stereotaxic apparatus (Stoelting Corp., Wood Dale, IL, USA) for cranial surgery. Body temperature was monitored throughout the surgical procedure and maintained at 371C by using a feedback-controlled heating device (Harvard Apparatus, Boston, MA, USA). Glass micropipettes (1.2 mm outer diameter; World Precisions Instruments, Inc., Sarasota, FL, USA) with tip diameters of 15 mm were backfilled with 10 ml of viral vector; SV(SOD1), SV(GPx1) or SV(BugT) which contains approximately 10 7 particles. 100 ng of gp120 was also injected using micropipettes into the caudate putamen 2 weeks post-transduction. The vector/gp120-filled micropipettes were placed into the caudate putamen (CP) using coordinates obtained from the rat brain atlas. For the injection into the CP, the burr hole was placed +0.48 mm anterior to bregma and À3.0 mm lateral to the sagittal suture. Once centered, the micropipette was placed 6.0 mm ventral from the top of the brain. The SV40 vectors and gp120 were administered by a Picospritzer II (General Valve Corp., Fairfield, NJ, USA) pulse of compressed N2 duration 10 ms at 20 psi until 10 ml was completely ejected from the pipette. Following the surgery, animals were housed individually with free access to water and food. After a survival period of 7 or 14 days, animals were anesthetized via intraperitoneal injection of sodium pentobarbital (Abbott Laboratories, North Chicago, IL, USA) (at 60 mg/kg) and perfused transcardially through the ascending aorta with 10 ml heparanized saline and 1000 ml of 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA, USA) in 0.1 M phosphate buffer (pH 7.4). The animals were analyzed for apoptosis post 24 h after injecting gp120 (100 ng). Immediately following perfusion-fixation, the rat brains were dissected out, placed in 4% paraformaldehyde for 24 h, then in a 30% sucrose solution for 24 h, then frozen in methyl butane cooled in liquid nitrogen. The samples were cut on a cryostat (10 mm sections). General morphology of the brain was assessed by neutral red (NR) staining performed on cryostat sections. Transduction was assessed for each injected brain CP injections by serial cryo-sectioning (10 mm thick coronal sections) and immunostaining of every 10th section for SOD1 or GPx1. For each rat, the numbers of transduced or apoptotic cells in one hemisphere were counted and summed. The longitudinal diffusion of the transgene away from the injection site was assessed as the distance comprised between the most distant sections anterior and posterior to the injection site demonstrating transgene expression. General morphology of the brain was assessed by neutral red (NR) staining performed on cryostat sections.
Immunostaining. Cells were grown either on 24-well plates or four-chamber slides treated with poly-D-lysine and matrigel. At the indicated times post-transduction, cells were fixed with 1% paraformaldehyde for 30 min on ice, permeabilized with 0.1% Triton X-100 in sodium citrate buffer. Nonspecific binding was blocked by treating cells with normal serum from the animal species Immunocytochemistry in vivo. For immunofluorescence, the coronal cryostat sections (10 mm thick) were processed for immunocytochemistry with an indirect immunofluorescence technique. After redydradation in 0.1 M PBS, pH 7.2, sections were permeabilized in PBS plus 0.1% Triton X-100 during 10 min, washed twice for 5 min in PBS, then stained by Neuro Trace (1:100) for 20 min at room temperature. The sections were washed in PBS plus 0.1% Triton X-100, then two times with PBS, and then allowed stand for 2 h at room temperature in PBS. Combination NeuroTrace-antibody staining, was performed using (anti-SOD1) staining first followed by staining with the fluorescent Nissl stain. Incubation with primary antibody was performed for 1 h and followed by incubation for 1 h with a secondary antibody diluted 1/ 100. Each incubation was followed by extensive washing with PBS. In order to stain the nuclei, the mounting medium contained DAPI (Vector Laboratories, Burlingame, CA, USA). Specimens were finally examined under a Leica DMRBE microscope (Leica Microsystems, Wetzlar, Germany). Negative controls consisted of preincubation with PBS and 0.1% BSA, substitution of nonimmune isotype-matched control antibody for primary antibody, and/or omission of the primary antibody.
Western analysis. Cells were grown on either 24-well plates or four-chamber slides treated with poly-D-lysine and matrigel. At the indicated times post-transduction, the mock-transduced cells were harvested by trypsinization and counted. The cells were lyzed by lysis buffer containing approtonin and phenyl methyl sulfonyl fluoride (PMSF). For in vivo protein analysis, brain sections were homogenized in buffer containing protease inhibitors and DNAse and cell lysates were prepared. Total protein was estimated using BCA protein assay kit (Pierce, Rockford, IL, USA). Total cell proteins (100 mg) were loaded in each well, then transferred to Immobilon-P poly vinylidine difluoride (PVDF) membrane (Millipore Inc., USA). Equal lane loading was assesed in the using anti-glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) antibody (1:5000). The blot was executed according to manufacturer's instructions (Roche). Anti-SOD1 and anti-GPx1 were used at dilutions of 1:500 and 1:100, respectively, and anti-mouse/anti-rabbit horseradish peroxidase (HRP) was used at a dilution of 1:5000 before addition of chemiluminiscence substrate (Roche).
Kinetic assays for SOD1 and GPx1 SOD1 activity. SOD1 activity was measured using SOD1 kit (R&D Systems, Minneapolis, MN, USA) according to manufacturer's instructions. Superoxide ions (O 2 À ) were generated by the action of xanthine oxidase (XOD) on xanthine. O 2 À ions convert NBT to NBT-diformazan, which absorbs light at 560 nm. Briefly, cell lysates were assayed for their ability to inhibit NBTdiformazan, which was converted to relative SOD activity. A standard curve for SOD1 was also generated in a range from 1 to 10 U activity points. The rate of increase in absorbance units (A) per minute was calculated as: A560nm at 5 : 30 À A560nm at 0 : 30 5 min ¼ D A560nm=min
The % Inhibition for the test sample was calculated as;
½ðD A560nm=minÞ ðNegative controlÞ À ðD A560nm=minÞtest ðD A560nm=minÞ ðNegative controlÞ Â100 ¼ %inhibition SOD activity was expressed as U/L from the SOD standard activity points. Unit of SOD was defined as amount of SOD which inhibits the rate of increase in absorbance due to NBT-diformazan formation by 50%.
GPx1 activity. GPx1 assay was performed following the manufacturer's instructions using a total GPx1 assay kit (Zeptometrix, Buffalo, NY, USA). Here, cumene hydroperoxide was used as the peroxide substrate (ROOH). Glutathione reductase (GSSG-R) and (b-nicotinamide adenine dinucleotide phosphate) NADPH were included in the reaction mixture. The change in A340 due to NADPH oxidation was monitored which indicated GPx1 activity. As all other reagents were present in excess, the amount of GPx1 was the rate limiting factor. The change in A340nm was monitored for 1 min, after a 40 s lag period.
Net Rate A340nm=min ¼ ðSample Rate A340nm=minÞ À ðBlank Rate A340nm=minÞ
GPx1 activity was calculated as:
GPx1 activity ðU=LÞ ¼ ½A340nm=min=EÂdÂTV=SV
Abbreviations: E, extinction coefficient for NADPH (0.00622 mM À1 cm À1 at 340 nm); d, cuvette path length; TV, Total volume; SV, Sample Volume.
Statistical analysis
Statistical analysis was performed using using Student's paired t-test for comparison between different groups.
